Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the ...

By Sukriti Gupta, Medha Singh and Nikhil Sharma (Reuters) -European shares ended slightly higher on Tuesday on the back of ...

Nordic stocks dropped Tuesday, with the OMX Nordic 40 Index declining 1.1%. Modern Times Group MTG AB Cl A posted the largest decline among large stocks during the session, dropping 9.2%, followed by ...

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

The FDA has received six adverse event reports connected to this specific lot of Ozempic (all submitted by Novo Nordisk), but ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as ...

During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...

Eurozone consumer confidence hits 18-month low as US tariffs bite. IMF cuts global growth forecasts while Lagarde urges ...

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...